Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H19N3O3S |
Molecular Weight | 357.427 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C3=CC=CC=N3
InChI
InChIKey=YASAKCUCGLMORW-UHFFFAOYSA-N
InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
Molecular Formula | C18H19N3O3S |
Molecular Weight | 357.427 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/rosiglitazone.html
http://www.rxlist.com/avandia-drug.htm
http://www.wikidoc.org/index.php/Rosiglitazone
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/rosiglitazone.html
http://www.rxlist.com/avandia-drug.htm
http://www.wikidoc.org/index.php/Rosiglitazone
Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. It is FDA approved for the treatment of as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Inhibitors of CYP2C8 (e.g., gemfibrozil) may increase rosiglitazone levels; inducers of CYP2C8 (e.g., rifampin) may decrease rosiglitazone levels. Common adverse reactions include edema, weight gain, and headache.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
40.0 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | AVANDIA Approved UseAfter consultation with a healthcare professional who has considered and advised the patient of the risks and benefits of rosiglitazone, AVANDAMET® is indicated as an adjunct to diet and exercise to improve glycemic control when treatment with both rosiglitazone and metformin is appropriate in adults with type 2 diabetes mellitus who either are: already taking rosiglitazone, or not already taking rosiglitazone and unable to achieve glycemic control on other diabetes medications and, in consultation with their healthcare provider, have decided not to take pioglitazone (ACTOS®) or pioglitazone-containing products (ACTOPLUS MET®, ACTOPLUS MET XR®, DUETACT®) for medical reasons. Other Important Limitations of Use: Due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. Therefore, AVANDAMET should not be used in patients with type 1 diabetes. Coadministration of AVANDAMET with insulin is not recommended [see Warnings and Precautions (5.2, 5.3) Launch Date1999 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
432 ng/mL DRUG LABEL https://www.fda.gov/media/75754/download |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
ROSIGLITAZONE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED |
|
598 ng/mL DRUG LABEL https://www.fda.gov/media/75754/download |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
ROSIGLITAZONE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2890 ng × h/mL DRUG LABEL https://www.fda.gov/media/75754/download |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
ROSIGLITAZONE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED |
|
2971 ng × h/mL DRUG LABEL https://www.fda.gov/media/75754/download |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
ROSIGLITAZONE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.59 h DRUG LABEL https://www.fda.gov/media/75754/download |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
ROSIGLITAZONE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED |
|
3.37 h DRUG LABEL https://www.fda.gov/media/75754/download |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: |
ROSIGLITAZONE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.105 |
unhealthy, 53.1 n = 32 Health Status: unhealthy Condition: Nonalcoholic steatohepatitis Age Group: 53.1 Sex: M+F Population Size: 32 Sources: Page: p.105 |
DLT: Headache, Malaise... Disc. AE: Pain in leg... Dose limiting toxicities: Headache (3.1%) AEs leading toMalaise (3.1%) Oedema legs (9.4%) discontinuation/dose reduction: Pain in leg (3.1%) Sources: Page: p.105 |
20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: Page: p.73,74 |
unhealthy, 60 n = 1 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 60 Sex: M Population Size: 1 Sources: Page: p.73,74 |
Disc. AE: Macular edema... AEs leading to discontinuation/dose reduction: Macular edema Sources: Page: p.73,74 |
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Type 2 diabetes mellitus Sources: Page: p.1 |
Disc. AE: Congestive heart failure, Myocardial ischemia... AEs leading to discontinuation/dose reduction: Congestive heart failure Sources: Page: p.1Myocardial ischemia (2%) Fluid retention Edema Weight gain Anemia Macular edema Fracture bone |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headache | 3.1% DLT |
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.105 |
unhealthy, 53.1 n = 32 Health Status: unhealthy Condition: Nonalcoholic steatohepatitis Age Group: 53.1 Sex: M+F Population Size: 32 Sources: Page: p.105 |
Malaise | 3.1% DLT |
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.105 |
unhealthy, 53.1 n = 32 Health Status: unhealthy Condition: Nonalcoholic steatohepatitis Age Group: 53.1 Sex: M+F Population Size: 32 Sources: Page: p.105 |
Pain in leg | 3.1% Disc. AE |
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.105 |
unhealthy, 53.1 n = 32 Health Status: unhealthy Condition: Nonalcoholic steatohepatitis Age Group: 53.1 Sex: M+F Population Size: 32 Sources: Page: p.105 |
Oedema legs | 9.4% DLT |
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.105 |
unhealthy, 53.1 n = 32 Health Status: unhealthy Condition: Nonalcoholic steatohepatitis Age Group: 53.1 Sex: M+F Population Size: 32 Sources: Page: p.105 |
Macular edema | Disc. AE | 20 mg single, oral Overdose Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: Page: p.73,74 |
unhealthy, 60 n = 1 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 60 Sex: M Population Size: 1 Sources: Page: p.73,74 |
Myocardial ischemia | 2% Disc. AE |
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Type 2 diabetes mellitus Sources: Page: p.1 |
Anemia | Disc. AE | 8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Type 2 diabetes mellitus Sources: Page: p.1 |
Congestive heart failure | Disc. AE | 8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Type 2 diabetes mellitus Sources: Page: p.1 |
Edema | Disc. AE | 8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Type 2 diabetes mellitus Sources: Page: p.1 |
Fluid retention | Disc. AE | 8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Type 2 diabetes mellitus Sources: Page: p.1 |
Fracture bone | Disc. AE | 8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Type 2 diabetes mellitus Sources: Page: p.1 |
Macular edema | Disc. AE | 8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Type 2 diabetes mellitus Sources: Page: p.1 |
Weight gain | Disc. AE | 8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Type 2 diabetes mellitus Sources: Page: p.1 |
PubMed
Title | Date | PubMed |
---|---|---|
Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation. | 2002 Apr |
|
Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes. | 2002 Jan |
|
Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. | 2002 Jun |
|
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. | 2002 Jun |
|
Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. | 2002 Jun |
|
Rosiglitazone-induced granulomatous hepatitis. | 2002 May-Jun |
|
Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. | 2002 Nov |
|
Accelerated hypertension due to rosiglitazone therapy. | 2002 Nov-Dec |
|
Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. | 2003 Apr |
|
15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. | 2003 Apr 25 |
|
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. | 2003 Feb 7 |
|
Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al. | 2003 Jan |
|
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. | 2003 Jan 1 |
|
Effects of rosiglitazone and linoleic acid on human preadipocyte differentiation. | 2003 Jul |
|
Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. | 2003 Jul 1 |
|
PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. | 2003 Oct |
|
Induction of apoptosis by mono(2-ethylhexyl)phthalate (MEHP) in U937 cells. | 2003 Oct 15 |
|
Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. | 2003 Sep |
|
Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. | 2003 Sep |
|
Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. | 2004 Apr |
|
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. | 2004 Aug |
|
Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice. | 2004 Aug |
|
Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. | 2004 Dec |
|
Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats. | 2004 Dec 1 |
|
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist. | 2004 Dec 15 |
|
Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. | 2004 Mar 23 |
|
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. | 2004 May |
|
Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. | 2004 May 15 |
|
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. | 2004 Nov |
|
Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. | 2004 Oct |
|
Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. | 2005 |
|
The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes. | 2005 |
|
Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. | 2005 Aug |
|
Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. | 2005 Feb |
|
The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. | 2005 Jan |
|
Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats. | 2005 Jun |
|
Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1. | 2005 Jun |
|
Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. | 2005 Mar |
|
The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. | 2005 Mar |
|
Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism. | 2005 Mar |
|
Development of a complex scintillation proximity assay for high-throughput screening of PPARgamma modulators. | 2005 Mar |
|
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. | 2005 Mar |
|
The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. | 2005 May |
|
Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. | 2005 May |
|
Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. | 2005 May |
|
Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. | 2005 May |
|
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. | 2005 May 12 |
|
Fatty acids and expression of adipokines. | 2005 May 30 |
|
Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. | 2005 Oct |
|
Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1. | 2005 Sep |
Sample Use Guides
Start at 4 mg daily in single or divided doses; do not exceed 8 mg daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18039959
Rosiglitazone treatment (5 uM) prevents NO and prostacyclin overproduction by inhibiting microparticles-induced iNOS and COX-2 expression.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:18:29 GMT 2023
by
admin
on
Fri Dec 15 16:18:29 GMT 2023
|
Record UNII |
05V02F2KDG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98241
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
NDF-RT |
N0000011272
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
WHO-ATC |
A10BD03
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
LIVERTOX |
NBK548114
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
NDF-RT |
N0000180190
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
WHO-ATC |
A10BD04
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
WHO-VATC |
QA10BG02
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
NDF-RT |
N0000175374
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
NCI_THESAURUS |
C1934
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
WHO-VATC |
QA10BD04
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
WHO-ATC |
A10BG02
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
NDF-RT |
N0000170119
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
NDF-RT |
N0000011272
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
WHO-VATC |
QA10BD03
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
NDF-RT |
N0000180186
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
NDF-RT |
N0000170119
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
||
|
NDF-RT |
N0000011272
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000089168
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
SUB10388MIG
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
2405
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
7662
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
77999
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
7555
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
DB00412
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
758698
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
Rosiglitazone
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
ROSIGLITAZONE
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
1056
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
05V02F2KDG
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
50122
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
C089730
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
C62076
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
DTXSID7037131
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
m9666
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
122320-73-4
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL121
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
05V02F2KDG
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | |||
|
84108
Created by
admin on Fri Dec 15 16:18:29 GMT 2023 , Edited by admin on Fri Dec 15 16:18:29 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR |
Binding Assay
IC50
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> INHIBITOR |
SUBSTRATE USED: Bromsulphthalein (BSP)
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
MINOR
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||